Results 31 to 40 of about 4,942 (259)

Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs [PDF]

, 2016
Background: Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular disease.
Cossu, M. (Maria), De Silvestro, G. (Giustina), Harada-Shiba, M. (Mariko), Julius, U. (Ulrich), Klör, H.U. (Hans U.), Moriarty, P.M. (Patrick M.), Pisciotta, L. (Livia), Schettler, V.J. (Volker J.), Soran, H. (Handrean), Stefanutti, C. (Claudia), Van Lennep, J.R. (Jeanine Roeters), Watts, G.F. (Gerald), Widhalm, K. (Kurt)   +12 more
core   +10 more sources

First clinical experiences with inclisiran in a real-world setting [PDF]

, 2023
Background and objective: Inclisiran is the first-in-class small interfering RNA (siRNA) PCSK9 inhibitor. In clinical trials inclisiran showed effective and sustained LDL-C reduction of ± 50 %.
Galema-Boers, Annette M.H., Mulder, Janneke W.C.M., Roeters van Lennep, Jeanine E.   +2 more
core   +2 more sources

Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway

Autoimmunity, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a well-known proprotein convertase that influences foam cell formation and modulates atherosclerosis. Inclisiran is a novel chemosynthetic small interfering RNA that inhibits PCSK9 synthesis.
Zhaoping Wang, Xiangyu Chen, Jingxing Liu, Yingcui Wang, Suhua Zhang   +4 more
doaj   +1 more source

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

American Journal of Preventive Cardiology, 2023
Patients with cerebrovascular disease (CeVD) have been shown to benefit from lipid-lowering therapies, but guideline-recommended levels of low-density lipoprotein cholesterol (LDL-C) are often not attained with statin treatment alone.
Wolfgang Koenig, Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, Gregory G. Schwartz, R. Scott Wright, Lorena Garcia Conde, Jackie Han, Frederick J. Raal   +8 more
doaj   +1 more source

Inclisiran: First Approval [PDF]

Drugs, 2021
Inclisiran (Leqvio®; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed ...
openaire   +2 more sources

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Frontiers in Pharmacology, 2023
Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD.
Yanzhen Zhang, Huaigang Chen, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Liu Yang, Fan Liu   +9 more
doaj   +1 more source

Inclisiran in lipid management: A Literature overview and future perspectives [PDF]

, 2021
Primary and secondary prevention protocols aim at reducing the plasma levels of lipids - with particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations – in order to improve the overall survival and reduce the occurrence ...
Caldarola P., Ciccone M. M., Colivicchi F., De Palo M., Gabrielli D., Mallamaci R., Massari F., Milo M., Scicchitano P.   +8 more
core   +1 more source

Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension [PDF]

, 2023
Small interfering RNA (siRNA) represents a novel, fascinating therapeutic strategy that allows for selective reduction in the production of a specific protein through RNA interference.
Allevi, Massimiliano, Di Pentima, Chiara, Giulietti, Federico, Landolfo, Matteo, Sarzani, Riccardo, Spannella, Francesco   +5 more
core   +1 more source

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Clinical and Translational Science, 2022
Inclisiran is a small interfering RNA molecule that has been shown to provide an effective and sustained reduction in low‐density lipoprotein cholesterol levels.
David Kallend, Jay Mason, Patrick F. Smith, Michael J. Koren, Robert Stoekenbroek, YanLing He, Peter Wijngaard   +6 more
doaj   +1 more source

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany [PDF]

, 2023
Background and aims Low-density lipoprotein cholesterol (LDL-C) is the main therapeutic target in the treatment of hypercholesterolemia. Small interfering RNA (siRNA) inclisiran is a new drug, which targets PCSK9 mRNA in the liver, reducing ...
Axthelm, C., Baessler, A., Doevelaar, A., Eitel, I., Geiling, J.-A., Kassner, U., Koenig, W., Kästner, U., Landmesser, U., Laufs, U., Lorenz, E., Makhmudova, U., Mensch, J., Paitazoglou, C., Perakakis, N., Rohn, B., Schatz, U., Scholl, M., Schulze, P. C., Schumann, F., Sinning, D. L., Stach, K., Steinhagen-Thiessen, E., Stürzebecher, P., Vogt, A., Weingärtner, Oliver, Westhoff, T.   +26 more
core   +1 more source